Compare Datadog Inc (DDOG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Sana Biotechnology Inc — how do they compare? Datadog Inc trades at $290.96 (market cap $98.31B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Datadog Inc is far larger — about 117.5× Sana Biotechnology Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Sana Biotechnology Inc for 23 Days on average.
| DDOG | SANA | |
|---|---|---|
Market Cap | $98.31B | $836.71M |
Volume | 2,936,660 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $288.15 | $5.92 |
52-Week Low | $102.62 | $2.68 |
Typical Hold Time | 76 Days | 23 Days |
Enterprise Value | $94.61B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $290.26, up 6.97% with strong bullish momentum approaching 52-week highs. The stock shows robust revenue growth reaching $3.43B in 2025, though profitability metrics remain mixed with a high P/E ratio of 547.6. Recent earnings beats and accelerating enterprise customer expansion support positive sentiment, while technical indicators show the stock trading near resistance at $288 with strong moving average support.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and AI-driven growth catalysts, though elevated valuation and negative cash flow trends present risks. The $276.10 consensus price target suggests limited upside from current levels, requiring continued execution on enterprise expansion and margin improvement to justify premium valuation.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
